西安2022年2月3日 /美通社/ -- 西安天美生物科技股份有限公司（納斯達(dá)克代碼：BON）（“天美生物”或“公司”），一家在天然、健康和個(gè)人護(hù)理行業(yè)提供關(guān)鍵活性成分及解決方案的領(lǐng)先供應(yīng)商，今天宣布其截至2021年9月30日的全年財(cái)務(wù)業(yè)績(jī)。
2021財(cái)年財(cái)務(wù)亮點(diǎn)
*本新聞稿末尾的附表包含財(cái)報(bào)的GAAP和非GAAP指標(biāo)的調(diào)整。關(guān)于我們非GAAP指標(biāo)的調(diào)整，請(qǐng)參見(jiàn)非GAAP財(cái)務(wù)指標(biāo)的解釋。
管理層討論
“我們對(duì)公司業(yè)務(wù)的強(qiáng)勁需求的趨勢(shì)感到高興，并且對(duì)公司實(shí)現(xiàn)了兩位數(shù)的銷售增長(zhǎng)和創(chuàng)下新高的收入感到自豪。這些結(jié)果充分的說(shuō)明了我們強(qiáng)大的產(chǎn)品力、持續(xù)創(chuàng)新能力、以及我們作為客戶重要合作伙伴的價(jià)值?！?天美生物公司董事長(zhǎng)兼CEO胡永衛(wèi)先生表示，“在短期內(nèi)，因?yàn)槿蛞咔榈木猛喜粵Q、全球貿(mào)易關(guān)系和宏觀經(jīng)融政策的變化，我們面臨著前所未有的全球供應(yīng)鏈挑戰(zhàn)以及通貨膨脹相關(guān)的原材料和物流相關(guān)成本的增加，但我相信我們團(tuán)隊(duì)完全有能力應(yīng)對(duì)這些困境和壓力。并且我們將“轉(zhuǎn)為危機(jī)”，以此為契機(jī)推動(dòng)公司的產(chǎn)品組合轉(zhuǎn)向更技術(shù)含量和更高利潤(rùn)的產(chǎn)品系列，以增加我們的定價(jià)能力，獲取更高的利潤(rùn)率；同時(shí)我們將提升優(yōu)化產(chǎn)能，并實(shí)施強(qiáng)而有力的成本控制措施。值得一提的是，我們以人體微生物為靶標(biāo)的終端系列產(chǎn)品2021年取得了顯著進(jìn)展，隨著我們?nèi)烊粋€(gè)人護(hù)理產(chǎn)品-羽淳的成功推出，以及水蘇糖益生菌粉等其他一系列產(chǎn)品陸續(xù)上市，在強(qiáng)大產(chǎn)品力和巨大市場(chǎng)需求的驅(qū)動(dòng)下，我們對(duì)自己在終端用戶市場(chǎng)快速取得的進(jìn)展有充分的信心。最后一點(diǎn)，隨著今年玉門工廠的完成投產(chǎn)，將能帶來(lái)150%的收入增長(zhǎng)，也使得我們能更高效地服務(wù)來(lái)自國(guó)內(nèi)外的客戶，加速我們的全球業(yè)務(wù)擴(kuò)張計(jì)劃，并為我們的投資者創(chuàng)造持久的長(zhǎng)期價(jià)值?！?nbsp;
2021財(cái)年產(chǎn)品（按類別）與上年相比增長(zhǎng)總結(jié)：
收入增加（減少） |
毛利潤(rùn)增加（減少） |
|
香料原料 |
61.7% |
82.3% |
膳食補(bǔ)充劑（固體飲料） |
71.2% |
81.8% |
生物活性食品原料 |
(5.6%) |
(14.2%) |
香料原料
膳食補(bǔ)充劑（固體飲料）
生物活性食品原料
銷售費(fèi)用從161,719美元減少到2021年同期的138,530美元，減少了23,189美元，或約14.3%。減少的原因是公司通過(guò)網(wǎng)絡(luò)營(yíng)銷和銷售推廣，將重點(diǎn)轉(zhuǎn)向國(guó)內(nèi)大型客戶，從而實(shí)現(xiàn)成本節(jié)約。
研究和開(kāi)發(fā)費(fèi)用從2020財(cái)年的205,359美元增長(zhǎng)至249,050美元，增長(zhǎng)了43,691美元，或約21.3%。增長(zhǎng)的主要原因是研究材料的消耗增長(zhǎng)了26,391美元以及研發(fā)測(cè)試和檢驗(yàn)相關(guān)的費(fèi)用增長(zhǎng)了10,647美元。
政府補(bǔ)貼以補(bǔ)貼形式獲得并確認(rèn)為其他營(yíng)業(yè)收入，在截至2021年9月30日和2020年9月30日的財(cái)年里，總額分別為446,910美元和332,418美元。
凈利潤(rùn)從截止至2020年9月30日財(cái)年的310萬(wàn)美元增長(zhǎng)至2021年同期的461萬(wàn)美元。
經(jīng)營(yíng)活動(dòng)產(chǎn)生的凈現(xiàn)金在截止至2021年9月30日的財(cái)年期間為405萬(wàn)美元，2020年同期為264萬(wàn)美元。
每股基本收益（“EPS”）為0.69美元，2020年同期為0.58美元。
稀釋后每股收益（“EPS”）為0.68美元，2020年同期為0.58美元。
報(bào)告期后事件
投資者電話會(huì)議和網(wǎng)絡(luò)直播
討論公司2021年財(cái)年財(cái)務(wù)業(yè)績(jī)的網(wǎng)絡(luò)直播將于2022年2月3日美國(guó)東部時(shí)間上午9:00開(kāi)始。網(wǎng)絡(luò)直播和相關(guān)PPT的獲取可以訪問(wèn)公司的投資者網(wǎng)站 https://ir.bnlus.com/events-presentations/。對(duì)于無(wú)法觀看網(wǎng)絡(luò)直播的人，在活動(dòng)結(jié)束后公司將在網(wǎng)站上提供錄制版本。
西安天美生物有限公司
西安天美生物專注于膳食營(yíng)養(yǎng)補(bǔ)充劑的生物活性成分的生產(chǎn)，如為食品制造商提供天然益生元；個(gè)人護(hù)理成分的生產(chǎn)，如為香水香料制造商提供從植物來(lái)源的香料原料，天然復(fù)配膳食補(bǔ)充劑生產(chǎn)，如固體飲料。欲了解更多信息，請(qǐng)?jiān)L問(wèn)公司網(wǎng)站：www.bnlus.com.
安全港聲明
本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關(guān)公司計(jì)劃、目標(biāo)、戰(zhàn)略、未來(lái)事件或業(yè)績(jī)的聲明，以及其他假設(shè)和不包含歷史事件的聲明。當(dāng)公司使用諸如“可能”、“將”、“打算”、“應(yīng)該”、“相信”、“期望”、“預(yù)期”、“計(jì)劃”、“估計(jì)”等或其他類似的表達(dá)方式，并不與歷史事件有關(guān)，就是在做前瞻性聲明。前瞻性聲明不是對(duì)公司未來(lái)業(yè)績(jī)的保證，涉及風(fēng)險(xiǎn)和不確定性，可能會(huì)導(dǎo)致實(shí)際結(jié)果與前瞻性聲明中討論的公司預(yù)期有實(shí)質(zhì)性的差異。這些陳述受不確定性和風(fēng)險(xiǎn)因素的印象，包括但不限于：公司的目標(biāo)和戰(zhàn)略、公司的未來(lái)業(yè)務(wù)發(fā)展、公司產(chǎn)品和服務(wù)的需求、技術(shù)的變化、經(jīng)濟(jì)狀況、中國(guó)天然健康和個(gè)人護(hù)理行業(yè)的發(fā)展及公司希望發(fā)展的其他國(guó)際市場(chǎng)、聲譽(yù)和品牌、競(jìng)爭(zhēng)和定價(jià)的影響、政府法規(guī)、中國(guó)及公司希望發(fā)展的其他國(guó)際市場(chǎng)的經(jīng)濟(jì)和商業(yè)狀況的變動(dòng)，以及與上述任何情況相關(guān)的假設(shè)和公司提交給SEC報(bào)告中所陳述的其他風(fēng)險(xiǎn)。因此，我們提醒投資者不要過(guò)分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素，這些文件可在www.sec.gov上查閱。公司不承擔(dān)公開(kāi)修訂本聲明日期之后出現(xiàn)的事件或情況的前瞻性聲明的義務(wù)。
更多信息，請(qǐng)聯(lián)系：
In the United States: |
In China: |
Maggie Zhang | Impact IR |
Sophie Zhang | Impact IR |
Phone: (646) 893-8916 |
Email: sophie.zhang@irimpact.com |
Email: maggie.zhang@irimpact.com |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
September 30 |
||||||||
2021 |
2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash |
$ |
1,903,867 |
$ |
53,106 |
||||
Short-term investments |
1,703,314 |
- |
||||||
Accounts receivable, net |
6,152,807 |
5,771,008 |
||||||
Inventories, net |
1,596,492 |
1,016,442 |
||||||
Advance to suppliers, net |
4,094,312 |
3,491,145 |
||||||
Deferred initial public offering costs |
- |
510,079 |
||||||
Acquisition deposit |
1,000,000 |
- |
||||||
Prepaid expenses and other current assets |
98,960 |
7,434 |
||||||
TOTAL CURRENT ASSETS |
16,549,752 |
10,840,214 |
||||||
Property, plant and equipment, net |
19,228,642 |
14,171,963 |
||||||
Intangible assets, net |
411,056 |
140,993 |
||||||
Right-of-use lease assets, net |
201,007 |
- |
||||||
Deferred tax assets, net |
22,342 |
49,059 |
||||||
TOTAL ASSETS |
$ |
36,412,799 |
$ |
25,202,229 |
||||
LIABILITIES AND EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Short-term loans |
$ |
41,381 |
$ |
1,289,081 |
||||
Current portion of long-term loans |
448,005 |
1,227,346 |
||||||
Third party loans |
- |
690,327 |
||||||
Accounts payable |
380,385 |
1,288,629 |
||||||
Due to related parties |
245,104 |
2,322,990 |
||||||
Taxes payable |
5,052,018 |
4,402,625 |
||||||
Deferred revenue |
1,096,101 |
385,978 |
||||||
Accrued expenses and other current liabilities |
41,711 |
56,604 |
||||||
Finance lease liabilities, current |
161,286 |
33,389 |
||||||
Operating lease liability, current |
62,871 |
- |
||||||
TOTAL CURRENT LIABILITIES |
$ |
7,528,862 |
$ |
11,696,969 |
||||
Long-term loans |
2,173,532 |
2,482,251 |
||||||
Finance lease liabilities, noncurrent |
28,953 |
- |
||||||
Operating lease liability, noncurrent |
146,703 |
- |
||||||
TOTAL LIABILITIES |
9,878,050 |
14,179,220 |
||||||
COMMITMENTS AND CONTINGENCIES |
- |
- |
||||||
EQUITY |
||||||||
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 8,330,000 and 5,800,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively |
$ |
833 |
$ |
580 |
||||
Additional paid in capital |
15,540,433 |
5,251,205 |
||||||
Statutory reserve |
1,050,721 |
579,922 |
||||||
Retained earnings |
9,192,676 |
5,072,672 |
||||||
Accumulated other comprehensive income (loss) |
222,221 |
(388,102) |
||||||
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY |
26,006,884 |
10,516,277 |
||||||
Non-controlling interest |
527,865 |
506,732 |
||||||
Total equity |
26,534,749 |
11,023,009 |
||||||
TOTAL LIABILITIES AND EQUITY |
$ |
36,412,799 |
$ |
25,202,229 |
||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
For the Years Ended September 30, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
REVENUE |
$ |
25,494,564 |
$ |
18,219,959 |
$ |
16,396,018 |
||||||
COST OF REVENUE |
(18,382,637) |
(13,017,646) |
(11,113,922) |
|||||||||
GROSS PROFIT |
7,111,927 |
5,202,313 |
5,282,096 |
|||||||||
OPERATING EXPENSES |
||||||||||||
Selling expenses |
(138,530) |
(161,719) |
(273,841) |
|||||||||
General and administrative expenses |
(1,323,726) |
(1,367,070) |
(1,310,215) |
|||||||||
Research and development expenses |
(249,050) |
(205,359) |
(522,867) |
|||||||||
Total operating expenses |
(1,711,306) |
(1,734,148) |
(2,106,923) |
|||||||||
INCOME FROM OPERATIONS |
5,400,621 |
3,468,165 |
3,175,173 |
|||||||||
OTHER INCOME (EXPENSES) |
||||||||||||
Interest income |
3,207 |
714 |
2,271 |
|||||||||
Interest expense |
(417,266) |
(329,102) |
(333,190) |
|||||||||
Unrealized foreign transaction exchange gain (loss) |
(45,124) |
(248) |
5,281 |
|||||||||
Gain on disposal of fixed assets |
- |
20,150 |
- |
|||||||||
Government subsidies |
449,972 |
362,187 |
140,295 |
|||||||||
Income from short-term investments |
565 |
- |
- |
|||||||||
Other income |
38,409 |
132,713 |
- |
|||||||||
Total other income (expenses), net |
29,763 |
186,414 |
(185,343) |
|||||||||
INCOME BEFORE INCOME TAX PROVISION |
5,430,384 |
3,654,579 |
2,989,830 |
|||||||||
INCOME TAX PROVISION |
(820,931) |
(556,262) |
(427,194) |
|||||||||
NET INCOME |
4,609,453 |
3,098,317 |
2,562,636 |
|||||||||
Less: net income (loss) attributable to non-controlling interest |
18,650 |
71,644 |
(11,167) |
|||||||||
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
$ |
4,590,803 |
$ |
3,026,673 |
$ |
2,573,803 |
||||||
OTHER COMPREHENSIVE INCOME (LOSS) |
||||||||||||
Total foreign currency translation adjustment |
612,806 |
450,234 |
(281,699) |
|||||||||
TOTAL COMPREHENSIVE INCOME |
5,222,259 |
3,548,551 |
2,280,937 |
|||||||||
Less: comprehensive income (loss) attributable to non-controlling interest |
21,133 |
81,737 |
(10,969) |
|||||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
$ |
5,201,126 |
$ |
3,466,814 |
$ |
2,291,906 |
||||||
EARNINGS PER SHARE |
||||||||||||
Basic |
$ |
0.69 |
$ |
0.58 |
$ |
0.50 |
||||||
Diluted |
$ |
0.68 |
$ |
0.58 |
$ |
0.50 |
||||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING |
||||||||||||
Basic |
6,615,833 |
5,210,649 |
5,166,667 |
|||||||||
Diluted |
6,706,235 |
5,210,649 |
5,166,667 |
|||||||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended September 30, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Cash flows from operating activities |
||||||||||||
Net income |
$ |
4,609,453 |
$ |
3,098,317 |
$ |
2,562,636 |
||||||
Adjustments to reconcile net income to cash provided by operating activities |
||||||||||||
Allowance for doubtful accounts |
2,948 |
22,137 |
34,328 |
|||||||||
Depreciation and amortization |
228,547 |
230,597 |
226,633 |
|||||||||
Inventory reserve (recovery) |
(312,532) |
29,539 |
- |
|||||||||
Deferred income tax |
29,109 |
(7,751) |
(5,149) |
|||||||||
Amortization of operating lease right-of-use assets |
58,147 |
- |
||||||||||
Amortization of stock options |
44,910 |
- |
- |
|||||||||
Unrealized foreign currency exchange loss (gain) |
45,124 |
248 |
(5,281) |
|||||||||
Gain on disposal of property and equipment |
- |
(20,150) |
- |
|||||||||
Changes in operating assets and liabilities: |
||||||||||||
Accounts receivable |
(89,543) |
(284,546) |
(2,912,222) |
|||||||||
Inventories |
(209,011) |
1,636,321 |
6,681,972 |
|||||||||
Advance to suppliers, net |
(399,262) |
(3,021,739) |
168,868 |
|||||||||
Prepaid expenses and other current assets |
2,642 |
72,116 |
173,609 |
|||||||||
Accounts payable |
(969,414) |
(1,982,205) |
(78,356) |
|||||||||
Operating lease liabilities |
(49,648) |
- |
- |
|||||||||
Taxes payable |
410,716 |
2,662,542 |
1,538,662 |
|||||||||
Deferred revenue |
684,030 |
161,045 |
(1,223,824) |
|||||||||
Accrued expenses and other current liabilities |
(33,092) |
46,605 |
(57,053) |
|||||||||
Net cash provided by operating activities |
4,053,124 |
2,643,076 |
7,104,823 |
|||||||||
Cash flows from investing activities |
||||||||||||
Purchase of short-term investments |
(2,159,920) |
- |
- |
|||||||||
Proceeds upon redemption of short-term investments |
470,082 |
- |
- |
|||||||||
Purchase of property and equipment |
(51,878) |
(31,885) |
(213,634) |
|||||||||
Capital expenditures on construction-in-progress |
(4,432,941) |
(4,301,103) |
(6,861,257) |
|||||||||
Purchase of intangible assets |
(269,088) |
- |
- |
|||||||||
Refund (payment) of acquisition deposit |
(1,000,000) |
1,329,945 |
(1,355,067) |
|||||||||
Net cash used in investing activities |
(7,443,745) |
(3,003,043) |
(8,429,958) |
|||||||||
Cash flows from financing activities |
||||||||||||
Net proceeds from issuance of Ordinary Shares in initial public offerings |
11,271,480 |
- |
- |
|||||||||
Proceeds from short-term loans |
1,257,225 |
2,033,570 |
4,008,293 |
|||||||||
Proceeds from long-term loans |
1,245,871 |
319,342 |
- |
|||||||||
Repayment of short-term loans |
(2,563,433) |
(2,872,778) |
(4,514,482) |
|||||||||
Repayment of long-term loans |
(2,522,101) |
- |
- |
|||||||||
Proceeds from (repayment of) borrowings from related parties |
(2,262,378) |
1,067,808 |
543,976 |
|||||||||
Proceeds from (repayment of) third party loans |
(721,484) |
238,133 |
(101,793) |
|||||||||
Principal payment from (repayment of) finance lease |
169,153 |
(392,030) |
432,722 |
|||||||||
Capital contribution from non-controlling interest |
- |
- |
435,964 |
|||||||||
Payment for deferred initial public offering costs |
(521,651) |
(281,553) |
- |
|||||||||
Net cash provided by financing activities |
5,352,682 |
112,492 |
804,680 |
|||||||||
Effect of changes of foreign exchange rates on cash |
(111,300) |
6,810 |
(6,630) |
|||||||||
Net increase (decrease) in cash |
1,850,761 |
(240,665) |
(527,085) |
|||||||||
Cash, beginning of year |
53,106 |
293,771 |
820,856 |
|||||||||
Cash, end of year |
$ |
1,903,867 |
$ |
53,106 |
$ |
293,771 |
||||||
Supplemental disclosure of cash flow information |
||||||||||||
Cash paid for interest expense |
$ |
417,266 |
$ |
276,671 |
$ |
333,190 |
||||||
Cash paid for income tax |
$ |
2,411 |
$ |
- |
$ |
115,179 |
||||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||||||
Amortization of share-based compensation for initial public offering services |
$ |
422,221 |
$ |
211,112 |
$ |
- |
||||||
Right-of-use assets obtained in exchange for operating lease obligations |
$ |
257,564 |
$ |
- |
$ |
- |
||||||
Bon Natural Life Limited
GAAP to Non-GAAP Reconciliation
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Adjusted EBITDA to Net Income |
|||||
30-Sep |
|||||
2021 |
2020 |
||||
Net income |
$ |
4,609,453 |
$ |
3,098,317 |
|
Interest expense |
417,266 |
329,102 |
|||
Income taxes |
820,931 |
556,262 |
|||
Depreciation and amortization |
228,547 |
230,597 |
|||
Non-cash item(1) |
44,910 |
- |
|||
Adjusted EBITDA |
$ |
6,121,107 |
$ |
4,214,278 |
|
(1) Non-cash item represents adjustment of stock-based compensation to reconcile net income to net cash provided by operations as presented on the Statement of Cash Flows
